Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single-cell RNA-sequencing of CD7 knockout CD8 T cells

ABSTRACT: Single-cell RNA-sequencing of CD7 knockout CD8 T cells

PROVIDER: PRJNA1196952 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Single-cell RNA-sequencing of CD7 knockout CD8 T cells

Project description:The goal of this study is to identify transcriptional changes in antigen-specific CD8 T cells caused by CD7 deletion.

2025-09-11 | GSE284072 | GEO

Bulk RNA-sequencing of CD7+ and CD7- CD8 T cells from chronic LCMV infection

Project description:The goal of this study is to determine transcriptional differences between PD-1+ CD7 hi and PD-1+ CD7 low CD8 T cells during chronic viral infection.

2025-09-11 | GSE284025 | GEO

Bulk RNA-sequencing of CD7+ and CD7- CD8 T cells from chronic LCMV infection

Project description:Bulk RNA-sequencing of CD7+ and CD7- CD8 T cells from chronic LCMV infection

| PRJNA1196868 | ENA

Efficacy-enhanced anti-CD7 universal chimeric antigen receptor-T cell therapy for relapsed/refractory CD7-positive hematological malignancies: A phase I clinical study

Project description:Chimeric antigen receptor-T cell (CAR-T) therapy in T cell malignancies faces fratricide, T cell aplasia, and product contamination. We developed an universal anti-CD7 CAR-T cells in which TRAC, CD7 and HLA-II were disrupted, while E-cadherin (a NK cell inhibitory molecule) was introduced, to mitigate graft versus host disease (GvHD), fratricide and rejection. Furthermore, we designed a subtle receptor, bbzg-CAR, comprising not only conventional domains (anti-CD7 scFv, 4-1BB co-stimulatory domain, and CD3ζ signaling domain), but also the intracellular domain of common γ chain. Bbzg-CAR-T exerted anti-tumor effects superior to those of conventional universal CAR-T cells. In adoptive therapy for relapsed/refractory (r/r) patients, no dose-limiting toxicity, GvHD, immune effector cell-associated neurotoxicity or severe cytokine release syndrome (grade≥3) was observed. Nine patients (82%) showed objective response with, complete response rates of 75% and 33.3% in r/r leukemia and lymphoma respectively. Preliminary safety and efficacy of this universal CAR-T product was achieved in CD7+ malignancies.

2022-09-08 | GSE192453 | GEO

Single-cell RNA sequencing of sstr2 knockout mice

Project description:Single-cell RNA sequencing of sstr2 knockout mice

| PRJNA699280 | ENA

Single cell RNA-sequencing of Zip8 knockout cells

Project description:Single cell RNA-sequencing of Zip8 knockout cells

| PRJNA777285 | ENA

Characterization of CD8+ virtual memory T cells in IL-4 knockout mice using single-cell RNA sequencing

Project description:Characterization of CD8+ virtual memory T cells in IL-4 knockout mice using single-cell RNA sequencing

| PRJNA1146335 | ENA

Single-cell RNA sequencing of sstr2 knockout mice

Project description:single-cell Gene expression signatures in gastric tissues of sstr2 knockout and wild type mice using Chromium’s 10x single-cell RNA-seq platform

2023-01-17 | GSE166113 | GEO

Single-cell RNA sequencing of OT-I CD8+ T cells after stimulation with different affinity ligands

Project description:Activation of CD8+ T cells depends exquisitely on the affinity of the T cell receptor (TCR) for a peptide MHC (pMHC) ligand complex. Here, we activated OT-I transgenic CD8+ T cells with pure peptide and examined early activation responses by single-cell RNA-sequencing. T cells were activated with the high affinity OT-I cognate peptide (N4=SIINFEKL) for 1, 3 or 6 hours, or with reduced affinity peptides (T4=SIITFEKL and G4=SIIGFEKL) or the non-binding peptide (NP68=ASNENMDAM) for 6 hours. Cells were then sorted into 96-well plates by FACS and RNA was sequenced following an adapted Smart-Seq2 protocol.

2018-06-25 | E-MTAB-6051 | biostudies-arrayexpress

CD7

Project description:CD7

2021-07-15 | OEX00013712 | NODE